Compare Berkshire Hathaway Inc Class B (BRK.B) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Berkshire Hathaway Inc Class B vs Viatris Inc — how do they compare? Berkshire Hathaway Inc Class B trades at $490.93, while Viatris Inc trades at $16.45 (market cap $18.99B). The key difference: Viatris Inc pays a 2.94% dividend while Berkshire Hathaway Inc Class B pays none, and Viatris Inc is trading nearer its 52-week high, Berkshire Hathaway Inc Class B nearer its low. Which is the better fit depends on your goals.
| BRK.B | VTRS | |
|---|---|---|
Sector | Financials | Health |
52-Week High | $513.70 | $17.39 |
52-Week Low | $459.10 | $8.74 |
Market Cap | — | $18.99B |
Enterprise Value | — | $31.20B |
Dividend Yield | — | 2.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BRK.B trades at $491.11, down 1.14% today, with a bullish technical signal driven by moving averages and an oversold 6-day RSI of 14.57. Support levels are firm near $483-$489, while resistance sits at $495-$501. Analyst consensus is positive with 57% buy ratings, though key financial ratios are unavailable in the provided data.
The outlook remains constructive given strong analyst support and technical oversold conditions, but risks include market volatility and reliance on Berkshire Hathaway's diverse portfolio performance. Upside depends on earnings momentum and macroeconomic stability.
Viatris (VTRS) trades at $16.39, up 0.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, with improving cash flow trends and a consensus price target of $20. Recent positive Phase 3 results for VR-205 and FDA acceptance of a new drug application highlight pipeline progress.
The outlook is mixed: strong analyst buy ratings and a 22% upside to target suggest value, but profitability challenges and high debt pose risks. Investors should weigh the potential from pipeline catalysts against ongoing margin pressure and competitive threats in the generic drug space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
